Summary
The effects of recombinant granulocyte colony-stimulating factor (rG-CSF) on the myelosuppression, especially neutropenia, induced by cancer chemotherapy in patients with urogenital cancer were investigated in a randomized, controlled clinical study. In this study, rG-CSF was given subcutaneously at a dose of 2 μg/kg per day for 14 consecutive days. Changes in neutrophil counts were compared between the first (no rG-CSF) and second cycles (rG-CSF treatment period) of chemotherapy. rG-CSF administration was found to be effective in reducing the duration of neutropenia, in elevating the neutrophil nadir, and in reducing recovery time. Based on comparisons between the randomized rG-CSF treatment group (with rG-CSF) and the control group, treatment with rG-CSF resulted in the moderation or prevention of neutropenia and the acceleration of recovery. These results demonstrate that in chemotherapy of patients with urogenital cancer, in which neutropenia is a dose- or schedule-limiting factor, the concomitant use of rG-CSF may enable an increase in the dose (higher single dose or increased dose per unit of time) or shorten the chemotherapy period.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Asano S, Ono M (1987) Human granulocyte colony-stimulating factor: its biological actions and clinical implication. Acta Haematol Jpn 50: 1550
Bronchud MH, Scarffe JH, Thatcher N, Crowther D, Souza LM, Alton NK, Testa NG, Dexter TM (1987) Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56: 809
Furue H, Hara Y, Imamura Y, Kimura T, Koyama Y, Kurihara M, Majima H, Nakao I, Niitani H, Ogawa M, Oonoshi T, Saito T, Sakai Y, Sakano T, Sakuma A, Takatani O, Tominaga S, Yokoyama M (1986) Response criteria of augmented effects of chemotherapy for solid cancer, the Japan Society for Cancer Therapy. J Jpn Soc Cancer Ther 21 (5): 943
Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MAS, Clarkson B, Oettgen, HF, Alton K, Welte K, Souza L (1899) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414
Morstyn G, Campbell L, Souza LM, Alton NK, Keech J, Green M, Sheridan W, Metacalf D, Fox R (1988) Effect of granulocyte colonystimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet I: 667
Ota K, Ariyoshi Y, Fukuoka M, Furuse K, Niitani H (1990) Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer. Jpn J Cancer Chemother 17: 65
Sekiya H, Moriya K, Sugano T, Wakabayashi K, Okazaki A (1989) Phase I clinical study of recombinant human G-CSF (rG-CSF for injection). Med Consult N Remed 26: 1660
Sternberg CN, Yagoda A, Scher HI, Watson RC, Herr HW, Morse MJ, Sogani PC, Vaughan ED Jr, Bander N, Weiselberg LR, Geller N, Hollander PS, Lipperman R, Fair WR, Whitmore WF Jr (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kotake, T., Miki, T., Akaza, H. et al. Effect of recombinant granulocyte colony-stimulating factor (rG-CSF) on chemotherapy-induced neutropenia in patients with urogenital cancer. Cancer Chemother. Pharmacol. 27, 253–257 (1991). https://doi.org/10.1007/BF00685108
Issue Date:
DOI: https://doi.org/10.1007/BF00685108